{
  "ticker": "JNJ",
  "target_date": "2025-01-09",
  "actual_date": "2025-01-08",
  "collected_at": "2025-12-08T11:15:24.596119",
  "price": {
    "open": 141.17,
    "high": 141.27,
    "low": 137.24,
    "close": 138.0443572998047,
    "volume": 11175600,
    "change_1d_pct": -2.71,
    "change_7d_pct": -1.92,
    "change_30d_pct": -7.58
  },
  "technicals": {
    "rsi_14": 37.62,
    "sma_20": 140.78,
    "sma_50": 146.12,
    "macd": -1.931,
    "macd_signal": -2.153,
    "macd_histogram": 0.222,
    "bb_upper": 143.82,
    "bb_lower": 137.74,
    "price_vs_sma20_pct": -1.95,
    "price_vs_sma50_pct": -5.53,
    "volume_ratio": 1.34
  },
  "fundamentals": {
    "market_cap": 488797798400,
    "pe_ratio": 19.583014,
    "forward_pe": 19.139622,
    "price_to_book": 6.1577687,
    "price_to_sales": 5.3044286,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.37,
    "pct_from_52w_low": 44.21
  },
  "macro": {
    "spy": {
      "price": 584.37,
      "change_1d_pct": 0.15,
      "change_7d_pct": 0.22
    },
    "vix": {
      "level": 17.7,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.69
    },
    "dollar_index": {
      "level": 109.18
    },
    "gold": {
      "price": 2683.8
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Strategically Building A $10,000 Dividend Portfolio: Realty Income As Its Core Position",
      "source": "SeekingAlpha",
      "datetime": 1736445600,
      "summary": "Learn how holding Realty Income as the largest position in your $10,000 dividend portfolio can reduce risk and maximize income and growth. Read more here.",
      "url": "https://finnhub.io/api/news?id=ed5b1ad88b48698ab02323e38e598afc36fca5294cd6b1542bb9dcba902b651f"
    },
    {
      "headline": "Contineum concludes enrolment in Phase II multiple sclerosis therapy trial",
      "source": "Yahoo",
      "datetime": 1736442003,
      "summary": "The trial is evaluating the efficacy and safety of PIPE-307 in RRMS patients.",
      "url": "https://finnhub.io/api/news?id=2ce3726f3e98b6b2d6e85d09d43de8c134b4195c4e1a03492dc1b9e022785690"
    },
    {
      "headline": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
      "source": "Yahoo",
      "datetime": 1736431213,
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=a52fd56805147b03f9a26a00088eb61fc6a96b27b24339bd9c03578d00d0dd01"
    },
    {
      "headline": "J&J Pauses Sales of Atrial Fibrillation Device, Stock Down",
      "source": "Yahoo",
      "datetime": 1736429460,
      "summary": "J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.",
      "url": "https://finnhub.io/api/news?id=dafcbc1711f31e1526350b7a6afdcf3e0fe9d2fe856f8c8baebde1ffe781afba"
    },
    {
      "headline": "Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis",
      "source": "Yahoo",
      "datetime": 1736427840,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis ",
      "url": "https://finnhub.io/api/news?id=27fa07e66074d80f69b7ba4f1015bae1ff8eb562f5e7d799691102a689c952eb"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734042449.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000106/xslF345X05/wk-form4_1734042449.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041779.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000104/xslF345X05/wk-form4_1734041779.xml"
    },
    {
      "form": "4",
      "date": "2024-12-12",
      "description": "xslF345X05/wk-form4_1734041373.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000102/xslF345X05/wk-form4_1734041373.xml"
    },
    {
      "form": "13F-HR",
      "date": "2024-11-13",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445424000604/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "10-Q",
      "date": "2024-10-23",
      "description": "jnj-20240929.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040624000096/jnj-20240929.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}